Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lisocabtagene maraleucel - Juno Therapeutics

Next Previous
Drug Profile

Lisocabtagene maraleucel - Juno Therapeutics

Alternative Names: anti-CD19-EGFRt-4-1BB-zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/EGFRt/4-1BB/zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; Breyanzi; CD19-directed chimeric antigen receptor T cell therapy - Juno Therapeutics; EGFRt-4-1BB-modified-CAR-CD8+-and-CD4+-T-lymphocytes-Juno-Therapeutics; Gene modified autologous T cells; JCAR 017; Liso-cel

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Juno Therapeutics
  • Developer Bristol-Myers Squibb; Celgene Corporation; Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma
  • Registered Chronic lymphocytic leukaemia; Follicular lymphoma
  • Preregistration Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase II B-cell lymphoma; Hodgkin's disease; Marginal zone B-cell lymphoma
  • Phase I/II Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 02 Apr 2024 Juno Therapeutics withdrawn phase III trial prior to enrollment for Chronic lymphocytic leukaemia (Second-line therapy or greater) in the US, Austria, Belgium, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, and the UK (IV, Infusion) due to changes in business objective(NCT06205290)
  • 15 Mar 2024 Registered for Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (IV)
  • 15 Mar 2024 Juno Therapeutics plans a phase III trial of Lisocabtagene maraleucel in Follicular lymphoma (Second-line therapy or greater) (IV) in March 2024 (NCT06313996)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top